Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 5/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 2/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878878 | 0.92 | LMNA (0.40) | ALOX5APMAPTPPARGROCK1MAPK8 | |
| SCHEMBL4871792 | 0.91 | PPARG (0.41) | ALOX5APMAPTPPARGROCK1MAPK8 | |
| SCHEMBL4867738 | 0.91 | PTGES (0.42) | ALOX5APMAPTPPARGMAPK8PTGES | |
| SCHEMBL4876397 | 0.89 | MAPT (0.37) | MAPTPPARGGPR55MAPK8PTGES | |
| SCHEMBL4871839 | 0.87 | ALOX5AP (0.40) | CSNK1DALOX5APMDM2 | |
| SCHEMBL4868490 | 0.86 | PPARG (0.43) | MAPTPPARGMAPK8PTGESCCR2 | |
| SCHEMBL4878217 | 0.86 | MAPT (0.39) | MAPTPPARGMAPK8CCR2 | |
| SCHEMBL4875185 | 0.85 | PPARG (0.40) | ALOX5APMAPTPPARGACP1ROCK1 | |
| SCHEMBL4868814 | 0.84 | EDNRB (0.39) | ALOX5APMAPTPPARGMAPK8CCR2 | |
| SCHEMBL4868351 | 0.84 | AKR1A1 (0.35) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | CSNK1D 1492/4885ALOX5AP 3943/4885MAPT 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.